Compare Alcon AG (ALC) vs NIO Inc. (NIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs NIO Inc. — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while NIO Inc. trades at $4.9 (market cap $12.57B). The key difference: Alcon AG is far larger — about 2.6× NIO Inc.'s market cap, and Alcon AG pays a 0.54% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| ALC | NIO | |
|---|---|---|
Market Cap | $32.69B | $12.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $7.89 |
52-Week Low | $62.02 | $3.48 |
Enterprise Value | $36.28B | $11.81B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
NIO trades at $4.88, up 1.88% with bearish technical signals despite strong delivery growth. The company shows improving fundamentals with revenue reaching $87.49B in 2025 and narrowing losses, though negative profitability metrics persist. Recent June deliveries surged 62.9% year-over-year, supporting margin expansion expectations. Analyst sentiment remains mixed with 50% buy ratings amid ongoing cash burn concerns.
NIO presents a high-risk turnaround opportunity with accelerating delivery growth and improving margins, but substantial losses and negative cash flow require careful monitoring. The stock faces technical resistance near $5 while benefiting from EV sector momentum and premium positioning in China's competitive market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
